Oic Pamora denied due to quantity / dose limits by Humana?

Humana's specific coverage criteria for oic pamora are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Imposes Quantity Limits on PAMORAs and How to Appeal

Humana's formulary typically includes quantity limits (QL) on peripherally acting mu-opioid receptor antagonists (PAMORAs) for opioid-induced constipation (OIC). Quantity limits cap the number of doses dispensed per fill or per month. A denial may occur if your prescription was written for a supply, strength, or frequency that exceeds the plan's default limit — even if your prescriber has determined that amount is medically appropriate for your situation.

### Why This Denial Is Appealable

Quantity limits are not absolute. When your prescriber documents a clinical reason why the standard limit is inadequate for your specific case — such as documented treatment-refractory OIC or a prescribed regimen that differs from the default — an exception or appeal can result in authorization of the requested quantity. Quantity-limit exceptions are a recognized category under both ERISA §503 and ACA §2719 appeal rights.

### Federal Appeal Framework

• Internal appeal: Request a quantity-limit exception or file a formal internal appeal within the period stated on your denial notice.
• External review (ACA §2719): If the internal appeal is denied, you may request independent external review, typically within four months of the final internal denial.
• Expedited review: Available when your clinical situation is urgent. Expedited external review generally resolves within 72 hours.

### Documentation to Gather

1. Prescriber rationale letter: A letter explaining why the prescribed quantity is medically necessary for your specific case — including the clinical basis for a supply or frequency that differs from the plan default. 2. Diagnosis and severity records: Chart notes confirming OIC diagnosis, severity, and its impact on adherence to opioid therapy for your underlying condition. 3. Prior-treatment response history: Documentation of how the medication has performed at various regimens, if applicable, to support the clinical need for the requested quantity. 4. FDA-approved prescribing information: The dosing guidance in the FDA label establishes the clinically appropriate range. If the prescribed quantity falls within the approved range, note that in the appeal. 5. Humana's quantity-limit policy: Request the current policy in writing so you can address each criterion directly.

### Criteria-Mapping Approach

Build a point-by-point response to Humana's quantity-limit policy criteria:

| Quantity-Limit Criterion | Supporting Evidence | |---|---| | Requested quantity within FDA-approved dosing range | [Reference to current prescribing label] | | Clinical justification for exceeding default limit | [Prescriber letter with clinical rationale] | | Documented inadequacy of lower quantity | [Chart notes, treatment history] | | Ongoing opioid therapy requiring OIC management | [Prescription records, chart notes] |

A well-documented quantity-limit exception request — anchored in the FDA label's approved dosing range and supported by a prescriber letter — gives the plan a clear clinical basis to approve the requested supply.